Observational analysis shows improved detection of gene fusions and deletions in cancer using ACTOnco+, indicating its potential for personalized medicine.
Key Points
ACTOnco+® identified 329 heterozygous deletions, demonstrating reliability with FISH analysis, and providing a robust genomic profile.
Positive agreement in actionable genes was 82.8% between ACTOnco+® and FoundationOne® CDx across 110 samples from 29 tumor types.
Comparison involved RNA and DNA analysis with high concordance in tumor mutational burden and microsatellite instability measurements.
The findings suggest that incorporating RNA analysis can enhance cancer genomic profiling for improved treatment strategies.